A detailed history of Yousif Capital Management, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Yousif Capital Management, LLC holds 35,806 shares of MYGN stock, worth $483,381. This represents 0.01% of its overall portfolio holdings.

Number of Shares
35,806
Previous 36,503 1.91%
Holding current value
$483,381
Previous $892,000 9.87%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$23.97 - $28.6 $16,707 - $19,934
-697 Reduced 1.91%
35,806 $980,000
Q2 2024

Jul 31, 2024

SELL
$17.98 - $25.47 $65,231 - $92,405
-3,628 Reduced 9.04%
36,503 $892,000
Q1 2024

Apr 26, 2024

SELL
$17.59 - $23.59 $69,744 - $93,534
-3,965 Reduced 8.99%
40,131 $855,000
Q4 2023

Feb 01, 2024

BUY
$13.91 - $21.32 $44,442 - $68,117
3,195 Added 7.81%
44,096 $843,000
Q3 2023

Oct 30, 2023

SELL
$15.99 - $23.22 $45,507 - $66,084
-2,846 Reduced 6.51%
40,901 $656,000
Q2 2023

Aug 02, 2023

SELL
$17.56 - $23.76 $36,226 - $49,016
-2,063 Reduced 4.5%
43,747 $1.01 Million
Q1 2023

May 02, 2023

SELL
$15.26 - $23.75 $90,797 - $141,312
-5,950 Reduced 11.5%
45,810 $1.06 Million
Q4 2022

Jan 09, 2023

SELL
$14.51 - $20.99 $197,118 - $285,149
-13,585 Reduced 20.79%
51,760 $0
Q3 2022

Nov 04, 2022

SELL
$18.21 - $27.88 $9,487 - $14,525
-521 Reduced 0.79%
65,345 $1.25 Million
Q2 2022

Aug 01, 2022

SELL
$16.45 - $25.88 $66,704 - $104,943
-4,055 Reduced 5.8%
65,866 $1.2 Million
Q1 2022

May 12, 2022

SELL
$22.67 - $28.01 $20,334 - $25,124
-897 Reduced 1.27%
69,921 $1.76 Million
Q4 2021

Jan 31, 2022

BUY
$24.13 - $32.63 $1.71 Million - $2.31 Million
70,818 New
70,818 $1.96 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.09B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.